Mindmed company information, Employees & Contact Information

MindMed Announces New Employee Inducement Grant Business Wire

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation in Adults with Generalized Anxiety Disorder Investing News Network

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Yahoo Finance

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 Business Wire

MindMed Appoints Matt Wiley as Chief Commercial Officer Business Wire

MindMed Reports Q2 2025 Financial Results and Business Updates Business Wire

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer Business Wire

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates Business Wire

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) Business Wire

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates Business Wire

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside ts2.tech

MindMed Expands Brain Health Team: Latest Stock Grants Signal Growth Push in Clinical Programs Stock Titan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder Business Wire

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) Business Wire

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy Business Wire

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) Business Wire

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) Yahoo Finance

MindMed Reports Third Quarter 2024 Financial Results and Business Updates Yahoo Finance

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering Business Wire

MindMed Announces Business Update and Anticipated Milestones for 2024 Business Wire

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) Business Wire

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder Business Wire

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) Business Wire

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results Psychedelic Alpha

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US Business Wire

MindMed (MMED) Psychedelic Alpha

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC Psychedelic Alpha

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company Psychedelic Alpha

MindMed Completes 1-for-15 Reverse Share Split PR Newswire

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD Psychedelic Alpha

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Psychedelic Alpha

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders Psychedelic Alpha

BREAKING: MindMed Applies to List on Nasdaq Psychedelic Alpha

MindMed: Phase 2 Clinical Trial of LSD for “Suicide Headaches” Begins Treating Patients Psychedelic Alpha

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics PR Newswire

MindMed Confirms No Material Change PR Newswire

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) Stock Titan

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies BioSpace

N.Y. company buys S.F. startup HealthMode to speed development of psychedelic drugs The Business Journals

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board citybiz

MindMed Completes Phase 1 LSD Dosing Study Psychedelic Alpha

Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine BioSpace

MindMed Completes 1-for-15 Reverse Share Split PR Newswire Canada

Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine PR Newswire

MindMed Drama: Freemans Attempt Board of Directors Takeover microdose.buzz

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience PR Newswire Canada

Kevin O’Leary-Backed MindMed Will Be 2nd Psychedelic Company to List On Nasdaq psychedelicspotlight.com

Is MindMed the NEXT Tesla? (MindMed Bull Thesis) psychedelicspotlight.com

Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine PR Newswire Canada

MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ] psychedelicspotlight.com

Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion) psychedelicspotlight.com